Comments
Drugmaker Cipla said the Konkan Division of the Food and Drugs Administration had ordered a suspension of the FDA licence to its manufacturing unit at Patalganga (Unit II) for 10 days in December 2023.
The reason mentioned is non-conformance of good manufacturing practices under the Drugs and Cosmetics Act, 1940.
Cipla said it was in the process of appealing the order to the State government, as it was “not in agreement with the FDA rulings, being the basis for the suspension”.
The order dated August 10, 2023, was received on August 14, said Cipla, and since it was issued in local vernacular language and due to national holiday on August 15, “there was a delay in interpretation and dissemination of the information within the prescribed timelines”.
Further, it added there was “no material impact on financials, operations or other activities of the Company due to the said order”. Cipla shares ended marginally down on the BSE at ₹1,238.75, on Thursday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.